Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06859294 · ClinicalTrials.gov registry record · Phase 2

A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

A Phase 2 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 2
Development phase
35
Enrollment target
20
Study locations

NCT06859294 is a Phase 2 study of Rheumatoid Arthritis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 35 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06859294, a Phase 2 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
35 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG LY3541860

Study Locations (20)

Arizona

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale - Avondale
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff - Flagstaff
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa - Mesa
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV - Phoenix
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City - Sun City
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast - Tucson

California

  • Medvin Clinical Research - Covina - Covina
  • Newport Huntington Medical Group - Huntington Beach
  • Medvin Clinical Research - Tujunga - Tujunga
  • Medvin Clinical Research - Whittier - Whittier

Florida

  • Clinical Research of West Florida, Inc. (Clearwater) - Clearwater
  • Clinical Research of West Florida - Tampa
  • Conquest Research - Winter Park

Texas

  • Accurate Clinical Management, LLC - Baytown
  • Accurate Clinical Research, Inc - Houston
  • DM Clinical Research - TRA - Tomball

Illinois

  • Willow Rheumatology and Wellness PLLC - Willowbrook

Louisiana

  • Accurate Clinical Research, Inc - Lake Charles

Minnesota

  • Saint Paul Rheumatology - Eagan

Pennsylvania

  • Altoona Center For Clinical Research - Duncansville

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2025-03-19
Est. Completion 2026-09
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06859294

The ClinicalTrials.gov registry entry for NCT06859294 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which LY3541860 is the first listed.

NCT06859294 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06859294 about?

NCT06859294 is a clinical study titled "A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis". The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic dru...

What is the current status of trial NCT06859294?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-03-19. Estimated completion is 2026-09.

What conditions does trial NCT06859294 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT06859294?

The interventions under investigation include: LY3541860 (DRUG).

Who is sponsoring clinical trial NCT06859294?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06859294 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.